MwanzoBIOVF • OTCMKTS
add
Swedish Orphan Biovitrum AB (publ)
Bei iliyotangulia
$Â 28.30
Bei za mwaka
$Â 22.87 - $Â 32.25
Thamani ya kampuni katika soko
117.48B SEK
Wastani wa hisa zilizouzwa
59.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
STO
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (SEK) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 6.89B | 33.40% |
Matumizi ya uendeshaji wa biashara | 3.52B | 4.14% |
Mapato halisi | 1.46B | 1,457.45% |
Kiwango cha faida halisi | 21.24 | 1,067.03% |
Mapato kwa kila hisa | 4.31 | 713.21% |
EBITDA | 3.00B | 89.53% |
Asilimia ya kodi ya mapato | 14.49% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (SEK) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 594.00M | -12.39% |
Jumla ya mali | 72.20B | -4.47% |
Jumla ya dhima | 35.09B | -14.71% |
Jumla ya hisa | 37.11B | — |
hisa zilizosalia | 343.44M | — |
Uwiano wa bei na thamani | 0.26 | — |
Faida inayotokana na mali | 7.15% | — |
Faida inayotokana mtaji | 9.59% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (SEK) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 1.46B | 1,457.45% |
Pesa kutokana na shughuli | 1.20B | 13.52% |
Pesa kutokana na uwekezaji | -2.20B | -431.88% |
Pesa kutokana na ufadhili | 860.00M | 211.11% |
Mabadiliko halisi ya pesa taslimu | -185.00M | -65.18% |
Mtiririko huru wa pesa | -3.51B | -219.76% |
Kuhusu
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
1939
Tovuti
Wafanyakazi
1,814
